Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Infection Control 'Urgently Needed' To Curb Spread Of XDR-TB Among Health Care Workers
Healthcare workers in South Africa are at a significantly increased risk of developing drug-resistant tuberculosis, or XDR-TB, in a trend which threatens to further exacerbate the already beleaguered healthcare systems in sub-Saharan countries, according to results of a new study. Researchers say the results underscore the urgent need for stringent TB screening policies among healthcare workers in these areas.

Prostate Cancer 'Homing Device' For Drug Delivery Created By Purdue Researchers
A new prostate cancer "homing device" could improve detection and allow for the first targeted treatment of the disease.
News of the day
Argenta Discovery And Porsolt Join Forces To Provide Fully-integrated CNS And Pain Contract Drug Discovery Services
Argenta Discovery and Porsolt announced they have entered into an alliance to provide unparalleled CNS and pain drug discovery services and expertise on a fee-for- service basis. The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for their clients, from hit identification to development candidate nomination. Both companies bring a wealth of "Big Pharma" industry based experience and know-how in CNS and pain research. This alliance will leverage those key skills for its partners to ensure the rapid generation of high quality development candidates.
Diagnostics

Foresight Biotherapeutics Announces Positive Results From An Open Label Pilot Study In Patients With Viral Conjunctivitis

Foresight Biotherapeutics, Inc. announced completion of a multi-center open-label pilot study of FST100 in the treatment of viral conjunctivitis. FST-100 is a novel formulation of dexamethasone that includes povidone iodine. The trial studied patients with clinical signs and symptoms of acute conjunctivitis who tested positive for adenoviral antigen by the RPS Adeno Detector® (RPS). Patients were enrolled in a single arm utilizing FST-100 topical ophthalmic suspension given 4 times daily for 5 days. The RPS Adeno Detector® test was performed at baseline and at each visit along with conjunctival swabs for adenoviral titers by quantitative PCR (qPCR) and cell culture with confirmatory immunoflourescence (CC-IFA). The primary endpoint of the study was clinical resolution of conjunctival injection and conjunctival discharge. These signs were scored on a scale from zero to three. Secondary endpoints included reduction of viral titers measured by qPCR and eradication of infectious virus determined by CC-IFA. FST-100 met the primary endpoint of the study by demonstrating complete resolution of conjunctivitis signs (a score of zero) in all eyes completing the study. One patient was lost to follow-up. In all RPS positive eyes with confirmed viral infection by qPCR and CC-IFA clinical symptoms resolved within 72 hours. All eyes completing the study with detectable adenovirus by qPCR demonstrated significant reduction in viral titers by 48-96 hours and the majority demonstrated elimination of infectivity by CC-IFA by 72-96 hours. There were no adverse events in the study. Lead investigator Jesse Pelletier, M.D. commented, "We are excited about this preliminary data and look forward to enrolling patients in a larger controlled clinical study. Currently, there are no drugs approved for the treatment of viral conjunctivitis and it is certainly an area of unmet medical need." Foresight Biotherapeutics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009